Top 5 Clean Energy Companies To Buy For 2014

It's been a long time coming for both natural gas and solar as viable sources of energy in the United States. Both have been struggling with a lack of consumer and industrial buy-in, but both could be right around the corner. Is either one standing out at the moment?

The debate is on
In the following video, Motley Fool analysts Joel South and Taylor Muckerman each weigh in on how natural gas and solar have been performing lately and which companies are taking the lead. Both options have made progress recently, with Clean Energy Fuels (NASDAQ: CLNE  ) building out its "America's Natural Gas Highway" initiative and SunPower (NASDAQ: SPWR  ) producing more efficient solar panels.

Has Clean Energy Fuels solved the "chicken-or-the-egg" debate?
The movement toward alternative energy is gaining momentum. One potential opportunity in this field is Clean Energy Fuels, which focuses its natural gas efforts primarily on trucking and fleets. It's poised to make a big impact on an essential industry. Learn everything you need to know about Clean Energy Fuels in The Motley Fool's premium research report on the company. Just click here now to claim your copy today.

Top 10 Recreation Companies To Buy For 2015: Nielsen Holdings NV (NLSN)

Nielsen Holdings N.V., incorporated on May 17, 2006, is a global information and measurement company. The Company delivers media and marketing information, and analytics on a global and local basis. It operates in three segments: Buy segment, Watch segment and Expositions segment. The Company�� Buy segment provides retail transactional measurement data, consumer behavior information and analytics primarily to businesses in the consumer packaged goods industry. Its Watch segment provides viewership data and analytics primarily to the media and advertising industries across television, online and mobile screens. The Company�� Expositions segment operates business-to-business trade shows and conference events in the United States. The Company�� clients include The Coca-Cola Company, NBC Universal, Nestle S.A., News Corp., The Procter & Gamble Company and the Unilever Group. In May 2011, it acquired NeuroFocus Inc. In August 2011, the Company acquired Marketing Analytics, Inc. In June 2013, Onex Corp announced that it has completed the acquisition of Nielsen Expositions from its parent, an affiliate of Nielsen Holdings NV (Nielsen).

What Consumers Buy

The Company�� Buy segment provides retail transactional measurement data, consumer behavior information and analytics primarily to businesses in the consumer packaged goods industry. This segment is organized into two areas: Information, which provides retail scanner and consumer panel-based measurement, and Insights, which provides a range of analytics. The Company�� consumer panels collect data from approximately 240,000 household panelists across 26 countries that use in-home scanners to record purchases from each shopping trip. Its analytical services are organized into seven primary categories: growth and demand strategy, market structure and segmentation, brand and portfolio management, product innovation services, pricing and sales modeling, retail marketing strategies and marketing return-on-investment (ROI) strate! gies.

What Consumers Watch

The Company�� Watch segment provides viewership data and analytics primarily to the media and advertising industries across television, online and mobile devices. It is engaged in the television audience measurement. The Company provides two principal television ratings services in the United States: measurement of national television audiences and measurement of local television audiences in all 210 designated local television markets. It measures television viewing in 28 countries outside the United States, including Australia, Indonesia, Italy, Mexico and South Korea. The Company is a global provider of Internet media and market research, audience analytics and social media measurement. Its online measurement service has a presence in 46 countries, including the United States, France, South Korea and Brazil. The Company provides critical advertising metrics, such as audience demographics, page and ad views, and time spent.

The Company provides independent measurement and consumer research for telecom and media companies in the mobile telecommunications industry. The Company offers mobile measurement services in 10 countries worldwide, including the United States. The Company develops advanced measurement techniques of the three principal screens: television, online and mobile devices. Its cross-platform measurement solution provides information about simultaneous usage of more than one screen, unduplicated reach, cause and effect analysis and program viewing behavior. It also provides advertising effectiveness research across multiple platforms. It also integrates data from its Buy segment with these measurement platforms.

The Company competes with GfK, Ipsos, Canoe Ventures, Dish Networks, WPP, Rentrak, TiVo, Mediametrie, Coremetrics, Google, Omniture, WebTrends, BuzzLogic, Cymfony and Umbria.

Advisors' Opinion:

• [By Dividend]

  Big names on the Buyback side were Pfizer (PFE), AbbVie, Canadian National Railway (CNI), Parker Hannfin (PH), Nielsen (NLSN) and CarMax (KMX).

  In total, 27 stocks announced a new, additional or increased share buyback program. The total buyback volume for the future is over USD $25 billion.

• [By Tom Taulli]

  Marketing. PEP remains on the cutting edge for marketing as well. Just recall the company�� “Crash the Super Bowl” campaign, which allowed fans to develop their own ads. For the 2013 game, the winning ad was ranked No. 1 for “most liked” and “most memorable” according to Nielsen (NLSN) ratings.�PEP is also aggressive with celebrity and athlete endorsements, as well as deals with organizations like the National Football League, Major League Baseball and National Hockey League. Beyonce at the Super Bowl, anyone? Retailers are more likely to carry PEP products because of these brand associations.

Top 5 Clean Energy Companies To Buy For 2014: PACCAR Inc.(PCAR)

PACCAR Inc, together with its subsidiaries, designs, manufactures, and distributes light-, medium-, and heavy-duty trucks and related aftermarket parts worldwide. The company offers its trucks for use in the over-the-road and off-highway hauling of freight, petroleum, wood products, construction, and other materials to independent dealers under the Kenworth, Peterbilt, and DAF nameplates. It also provides finance and leasing products and services, such as inventory financing for independent dealers; and retail loan and lease financing for new and used trucks, as well as other transportation equipment; and full service leasing under the PacLease trade name. In addition, it manufactures and sells industrial winches under the Braden, Carco, and Gearmatic nameplates. PACCAR Inc was founded in 1905 and is headquartered in Bellevue, Washington.

Advisors' Opinion:

• [By Neha Chamaria]

  Investors who follow the industrial sector closely should be ready for a busy week ahead, as some of the top names turn up with their quarterly earnings reports. One company to pay attention to is PACCAR (NASDAQ: PCAR  ) .

• [By MONEYMORNING.COM]

  Here, we're talking about companies like coffee giant Starbucks Corp. (Nasdaq: SBUX), mutual fund player T. Rowe Price Group Inc. (Nasdaq: TROW), and Peterbilt truck maker PACCAR Inc. (Nasdaq: PCAR).

• [By Peter Graham]

  The Q2 2014 earnings report for Navistar International Corp (NYSE: NAV), a potential peer of light, medium- and heavy-duty truck or engine makers PACCAR Inc (NASDAQ: PCAR) and Cummins Inc (NYSE: CMI), is scheduled to report earnings after the market closes on Thursday.�Aside from the Navistar International Corp earnings report, it should be said that PACCAR Inc and Cummins Inc both�reported Q1 2014 earnings on April 29th (PCAR reported higher revenues and net income�while CMI hit a�52-week high after a beat and raised guidance). However, Navistar International Corp�has lost market share since 2012 when�US regulators denied approval of a redesigned diesel engine that failed to reduce green house gas levels���forcing the company to turn to�rival Cummins Inc to supply engines as it develops its own catalytic reduction engines to reduce nitrogen oxide emissions.��

• [By Brian Stoffel]

  The business from PACCAR (NASDAQ: PCAR  ) in particular, is important to Cummins. In 2012, PACCAR accounted for 13% of Cummins' consolidated net sales. If any of these companies were to switch to a different engine maker, or choose to make their own engines in-house, it would likely cause a noticeable decline in revenue.

Top 5 Clean Energy Companies To Buy For 2014: BioTime Inc (BTX)

BioTime, Inc., incorporated on November 30, 1990, is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. On March 21, 2011, the Company acquired Glycosan BioSystems, Inc. (Glycosan) through a merger of Glycosan with OrthoCyte Corporation (OrthoCyte). Through the merger, OrthoCyte acquired all of Glycosan�� assets, including Glycosan�� Hystem hydrogel product line. In March 2011, the Company entered into an agreement with XenneX, Inc., pursuant to which it organized LifeMap Sciences, Inc. (LifeMap), a subsidiary formed to advance the development and commercialization of its human embryonic stem (hES) cell data base. In August 2011, four hES cell lines (ESI-035, ESI-049, ESI-051 and ESI-053) developed by its subsidiary ES Cell International (ESI) were approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. In May 2012, the Company acquired XenneX, Inc., through a merger of XenneX into LifeMap Sciences. In September 2012, the Company formed a wholly owned subsidiary, BioTime Acquisition Corporation. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

HyStem is a biomaterial, which mimics the human extracellular matrix, which is the network of molecules surrounding cells in organs and tissues which is essent! ial to cellular function. Its HyStem hydrogels may have other applications when combined with the diverse and scalable cell types its scientists have isolated from hES cells. HyStem-Rx is a clinical grade formulation of HyStem-C, a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. Its subsidiary, OncoCyte Corporation, is developing PanC-Dx, a non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. BioTime Asia, Limited (BioTime Asia) sells products for research use and may develop therapies to treat cancer and neurological and orthopedic diseases in Asia. OrthoCyte Corporation (OrthoCyte) is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (ReCyte Therapeutics) is developing therapies for age-related cardiovascular and blood disorders. Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences), is a biotechnology company focused on developing stem cell-based therapies for retinal and other neurological disorders, including the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. LifeMap Sciences, Inc. (LifeMap) is advancing the development and commercialization of our embryonic stem cell database and plans to make the database available for the marketing of research products and for use by stem cell researchers at pharmaceutical and biotechnology companies and other institutions via paid subscriptions or on a fee per use basis.

The Company�� blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia, a condition caused by low blood volume, often from blood loss during surgery or injury. Hextend maintains circulatory system fluid volume and blood pressure, and keeps vital organs perfused during surgery and t! rauma car! e. Hextend is manufactured and distributed in the United States by Hospira, Inc., and in South Korea by CJ CheilJedang (CJ), under license from it.

Human Embryonic Stem Cell Lines for Research Use

Combined with the Company�� ACTCellerate technology, it derives of a range of markets human embryonic progenitor cells (hEPCs). ESI�� six current good manufacturing practices (cGMP) hES cell lines have been approved by the NIH for inclusion in the Human Embryonic Stem Cell Registry, which renders those cell lines eligible for use in federally funded research. The ESI hES cell lines are available for purchase through www.biotimeinc.com. It also markets hEPCs developed using ACTCellerate technology. Its hEPCs are also available for sale through www.biotimeinc.com. It derived the complete genome sequence of five of the ESI hES cell lines to facilitate the development of products derived from these cell lines. It has made these GMP-grade cell lines, along with certain documentation and complete genomic deoxyribonucleic acid (DNA) sequence information, available for sale.

The Company offers human stem cell products and technology that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. It has developed research and clinical grade hES cell lines, which it markets for both basic research and therapeutic product development. It also markets human embryonic progenitor cell (hEPCs) developed using ACTCellerate technology. These hEPCs are purified lineages of cells, which are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The ACTCellerate cell lines are also available for purchase through http://www.biotimeinc.com.

Human Embryonic Progenitor Cells

Through the Company�� subsidiary ReCyte Therapeutics, it had a license from Advanced Cell Technology, Inc. (ACT) to use ACTCellerate technology, and the rights to market more than 200 human c! ell types! made using that process. ACTCellerate allows the rapid isolation of hEPCs, which are cells that are intermediate in the developmental process between embryonic stem cells and fully differentiated cells.

Through an agreement with ReCyte Therapeutics, Millipore Corporation became a global distributor of ACTCellerate hEPC lines. In addition to the products, which it is co-marketing with Millipore, it offers 92 other ACTCellerate hEPC lines for purchase at www.biotimeinc.com. Through its subsidiary LifeMap, it provides online biomedical database services to increase awareness of molecular markers and diverse cell types comprising its ACTCellerate hEPC lines. It also focuses to market additional cell types manufactured with its PureStem technology. PureStem cell lines are produced by the exogenous expression of specific transcription factors, which regulate the differentiation of cell types from hES or induced pluripotent stem (iPS) cells. BioTime Asia has an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate hEPC lines and related ESpan growth media to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau on an exclusive basis. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to maintain exclusivity. The Company�� California Institute of Regenerative Medicine (CIRM)-funded research addresses the need for industrial scale production of purified therapeutic cells.

hES Cells Carrying Genetic Diseases

The Company focuses to add to its product line muscle progenitor cells produced from five hES cell lines carrying genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. It obtained the diseased hES cell lines from Reproductive Genetics Institute (RGI).

ESpan Cell Growth Media

The Company is marketing a range of! cell-gro! wth media products called ESpan. These growth media are optimized for the growth of hEPC types. Cells need to be propagated in liquid media, in both the laboratory setting, where basic research on stem cells is performed, and in the commercial sector. Its ESpan products are marketed through Millipore and Genext.

ESpy Cell Lines

The Company focuses for development of ESpy cell lines. The ability of the ESpy cells to emit light will allow researchers to track the location and distribution of the cells in both in vitro and in vivo studies.

HyStem Hydrogel for Research and HyStem-Rx for Cell Delivery Medical Devices

HyStem is a patented biomaterial that mimics the ECM, the network of molecules surrounding cells in organs and tissues that is essential to cellular function. Its HyStem technology forms the foundation for stem cell delivery products in both the adult and embryonic stem cell marketplace, including products manufactured using its ACTCellerate technology. As an injectable product, HyStem-Rx may address need in cosmetic and reconstructive surgeries and other procedures by transplanting adipose derived cells or other adult stem cells. The transfer of cells in HyStem-Rx localizes the transplanted cells at the intended site and by providing a three-dimensional scaffold upon which cells can rebuild normal tissue. HyStem-Rx may support other emerging cell and tissue transplant therapies, such as those derived from hES and iPS cells, in addition to its potential application in the treatment of a range of conditions such as osteoarthritis, brain tumors, stroke, bone fracture, and wounds.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX  ) has received the dreaded one-star ranking.

• [By John Udovich]

  Stem cell stocks have not exactly been the best performers lately in part because the controversy over their use has died down over the years while major breakthroughs have been few or far between, but the industry along with small cap stem cell stocks Pluristem Therapeutics Inc (NASDAQ: PSTI), BioTime, Inc (NYSEMKT: BTX) and BioRestorative Therapies (OTCBB: BRTX) are still quietly producing their share of news or minor breakthroughs worth taking note of. Just consider the following stem cell news or news from small cap players in the sector:

Top 5 Clean Energy Companies To Buy For 2014: Cornerstone Total Return Fund Inc (CRF)

Cornerstone Total Return Fund, Inc. (the Fund) is a closed-end, diversified management investment company. Its investment objective is to seek capital appreciation with current income as a secondary objective. The Fund may invest without limitation in other closed-end investment companies and ETFs, provided that the Fund limits its investment in securities issued by other investment companies so that not more than 3% of the outstanding voting stock of any one investment company will be owned by the Fund. It invests in sectors, such as information technology, industrial, financials, healthcare, energy, consumer discretionary and consumer staples. The Fund is managed by Cornerstone Advisors, Inc. Advisors' Opinion:

• [By Dividends4Life]

  According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer